F9 and hemophilia B: Another option is using FVIIa in gene therapy for hemophilia B as a bypassing agent to promote blood clotting, as this factor can activate the coagulation cascade independently of factor IX [57] or FVa, which has the capacity to enhance the rate of thrombin generation almost 10,000 fold [58].